Preclinical News and Research

RSS
Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

FVCG portfolio companies selected to present research at Bio International 2015

FVCG portfolio companies selected to present research at Bio International 2015

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Study sheds light on genetic differences between colorectal cancer in older and younger patients

Study sheds light on genetic differences between colorectal cancer in older and younger patients

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Study reveals new molecular mechanism that helps protect genome from harmful effect of UV radiations

Study reveals new molecular mechanism that helps protect genome from harmful effect of UV radiations

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

GHIT Fund expands investments in leishmaniasis, diagnostic tests

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Heart rate measures could identify individuals with higher risk of diabetes

Heart rate measures could identify individuals with higher risk of diabetes

MR Solutions launches conversion kit that can transform clinical MRI scanner into a preclinical system

MR Solutions launches conversion kit that can transform clinical MRI scanner into a preclinical system

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.